| Mountain Comprehensive Health Corporation | |
|
1620 E Main St Cumberland KY 40823-1837 | |
| (606) 589-6113 | |
| (606) 589-4436 |
| Full Name | Mountain Comprehensive Health Corporation |
|---|---|
| Speciality | Clinic/Center |
| Location | 1620 E Main St, Cumberland, Kentucky |
| Authorized Official Name and Position | L,m. Caudill (CHIEF EXECUTIVE OFFICER) |
| Authorized Official Contact | 6066334823 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Mountain Comprehensive Health Corporation Po Box 40 Whitesburg KY 41858-0040 Ph: (606) 633-4823 | Mountain Comprehensive Health Corporation 1620 E Main St Cumberland KY 40823-1837 Ph: (606) 589-6113 |
| NPI Number | 1992251185 |
|---|---|
| Provider Enumeration Date | 08/29/2016 |
| Last Update Date | 07/06/2021 |
| Medicare PECOS PAC ID | 7618875873 |
|---|---|
| Medicare Enrollment ID | O20161018000929 |
News Archive
The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.
Food is an integral part of life; but, for some, it can be harmful. Allergic inflammation caused by inappropriate immune responses to some types of food has become a major public health issue. Over the past ten years, the prevalence of food allergies has increased by nearly 20 percent, affecting an estimated six million people in the U.S.
The Endocrine Society is calling on policymakers to include government negotiation as part of an overall strategy to reduce insulin prices in its updated position statement published today in The Journal of Clinical Endocrinology & Metabolism.
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Viread® (tenofovir disoproxil fumarate).
› Verified 4 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992251185 | NPI | - | NPPES |
News Archive
The Zilver PTX Drug-Eluting Stent, the first device of its kind developed to treat peripheral artery disease (PAD) in the superficial femoral artery (SFA), has received a unanimous recommendation from the Food and Drug Administration's (FDA) Circulatory System Devices Panel of the Medical Devices Advisory Committee, Cook Medical announced today.
Food is an integral part of life; but, for some, it can be harmful. Allergic inflammation caused by inappropriate immune responses to some types of food has become a major public health issue. Over the past ten years, the prevalence of food allergies has increased by nearly 20 percent, affecting an estimated six million people in the U.S.
The Endocrine Society is calling on policymakers to include government negotiation as part of an overall strategy to reduce insulin prices in its updated position statement published today in The Journal of Clinical Endocrinology & Metabolism.
Gilead Sciences, Inc. today announced receipt of a Paragraph IV Certification Notice Letter advising that Teva Pharmaceuticals submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) requesting permission to manufacture and market a generic version of Viread® (tenofovir disoproxil fumarate).
› Verified 4 days ago